Moderna says the FDA refused to file its application for an mRNA flu vaccine, citing problems with the trial comparator, and the company is pushing back while regulatory scrutiny grows under Health Secretary Robert F. Kennedy Jr. The decision could slow a shot aimed at better protecting older Americans, and Moderna plans to press for a prompt meeting with the agency while reviews continue overseas.
The FDA issued a refusal-to-file letter citing the lack of an “adequate and well-controlled” study with a comparator arm it considered to be the best-available standard of care. Moderna says it used a licensed standard-dose seasonal flu vaccine as the comparator and believes that choice was consistent with prior guidance. The company says the agency never flagged a problem before the trial began.
Stéphane Bancel, chief executive officer of Moderna, said the FDA’s decision did not “identify any safety or efficacy concerns with our product” and “does not further our shared goal of enhancing America’s leadership in developing innovative medicines.” He framed the issue as procedural, not scientific, and called for a quick path forward. That distinction matters for a company betting on mRNA to change how we fight seasonal flu.
“It should not be controversial to conduct a comprehensive review of a flu vaccine submission that uses an FDA-approved vaccine as a comparator in a study that was discussed and agreed on with CBER prior to starting,” Bancel said in a statement. “We look forward to engaging with CBER to understand the path forward as quickly as possible so that America’s seniors, and those with underlying conditions, continue to have access to American-made innovations.” Moderna has formally requested a Type A meeting to clarify the agency’s position.
RFK JR. DEFENDS FIRING SPREE AT CDC, VOWS ‘NEW BLOOD’ AT AGENCY The move from FDA comes as Robert F. Kennedy Jr. has shaken up vaccine policy and oversight, drawing a lot of attention inside and outside government. Republicans who value clear, science-based standards are watching this unfold with concern, since shifting political winds can slow approvals for real-world medical progress. The bigger issue here is consistency and predictability in the regulatory process.
Kennedy has criticized mRNA technology publicly and taken steps to change advisory panels and cancel contracts tied to those vaccines. That context matters because it raises questions about whether politics, policy, or science were the dominant factor in this review. Regulators must show they are driven by data and not headlines. The stakes are especially high for seniors and people with chronic conditions.
SEN BERNIE SANDERS CALLS ON RFK JR TO RESIGN FOLLOWING DEPARTURE OF CDC OFFICIALS Moderna says the FDA’s refusal contradicts prior written communications, including guidance from earlier in 2024 indicating a standard-dose comparator would be acceptable with caveats for older participants. The company argues it followed the protocol the agency reviewed before the trial began in September 2024. That timeline of pre-submission discussions is central to Moderna’s complaint about an unexpected refusal-to-file.
Moderna notes that after finishing its Phase 3 efficacy trial, it provided additional supportive analyses requested by the agency and that no clinical hold was raised before the study started. Now the company is pressing for clarification while regulatory work continues in the EU, Canada and Australia. Those parallel reviews will matter if the U.S. process stalls and Americans fall behind on access to new technology.
RFK JR LAUNCHES INVESTIGATION INTO SCHOOL FOR ALLEGED VACCINATION OF CHILD WITHOUT PARENTAL CONSENT Beyond the comparator dispute, this episode highlights a deeper tension: regulators must protect public safety while also encouraging medical innovation. Republicans generally want a predictable, fair process that rewards companies following agreed pathways and avoids surprise refusals. If agencies change the rules midstream, that chills investment and delays benefits for patients.
The refusal-to-file specifically referenced Moderna’s choice of comparator, saying it did not reflect the “best-available standard of care” for older adults. Moderna insists the agency had previously signaled acceptance and that any preference for a higher-dose comparator should have been raised earlier. The back-and-forth will likely move fast now that a Type A meeting has been requested.
Moderna also said regulatory reviews are proceeding outside the United States, and the company wants to keep momentum on a product aimed at improving protection for older Americans. The company’s stance is straightforward: clear rules, consistent feedback, and a fast resolution so seniors are not left waiting for better options. That argument resonates with anyone who expects Washington to back American innovation rather than slow it down.
